Fundraising Fox
Alector
NASDAQ: ALECUnicorn · $1.9BSan Francisco, US · Founded 2013 · Delaware LLC · 131 employees on LinkedIn · 7 known investors
Find your way into Alector
Sign up to see every warm intro you have to Alector
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Alector team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Alector develops therapies targeting neurodegenerative diseases including Alzheimer's, frontotemporal dementia, and Parkinson's disease through protein removal, replacement, and immune cell restoration. The company focuses on patients with neurodegenerative conditions and applies genetics, neuroscience, and immunology to advance new treatments.
Founders & leadership
Alector was founded in 2013 by Arnon Rosenthal and Tillman Gerngross.
Board
Investors · 7
How we know: Foresite Capital's portfolio page · Not right? Tell us
How we know: GV (Google Ventures)'s portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Mission Biocapital's portfolio page · the VCSheet dataset · Not right? Tell us
How we know: MRL Ventures Fund's portfolio page · the S-1 prospectus · Not right? Tell us
How we know: SV Health Investors's portfolio page · Not right? Tell us
How we know: a partner's Signal profile · board seat on SEC Form D · Not right? Tell us
Funding
SEC filings, press & company announcements$32.3M disclosed across 1 of 2 rounds · 2015–2018
- Undisclosed amountSeries EJul 2018Source ↗
▶$32.3MraisedSep 2015 · 11 investors · BiotechnologyRule 506(b)
- Carl GordonDirector
- Tillman GerngrossDirector
- Arnon RosenthalExecutive Officer, Director
- Terry McGuireDirector
- Offering amount
- $32.3M
- Amount sold
- $32.3M
- First sale
- Sep 2015
- Incorporated
- Limited Liability Company, Delaware, 2013
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Founder mafia
3 people who came through Alector went on to found or lead other companies.
Related companies · 4
Companies working in the same space as Alector.
Frequently asked questions
- What does Alector do?
- Alector develops therapies targeting neurodegenerative diseases including Alzheimer's, frontotemporal dementia, and Parkinson's disease through protein removal, replacement, and immune cell restoration. The company focuses on patients with neurodegenerative conditions and applies genetics, neuroscience, and immunology to advance new treatments.
- Who founded Alector?
- Alector was founded by Arnon Rosenthal, Tillman Gerngross in 2013.
- Who are Alector's investors?
- Alector's investors include Foresite Capital, GV (Google Ventures), Mission Bay Capital, Mission Biocapital, MRL Ventures Fund, SV Health Investors, Polaris Partners.
- How much funding has Alector raised?
- Alector has disclosed $32.3M raised across 1 of its 2 known rounds.
- Where is Alector headquartered?
- Alector is headquartered in San Francisco, US.